Results 311 to 320 of about 154,558 (375)

Bimodal intensity-modulated radiotherapy in combination with carbon ion therapy (C12) of mucosal melanomas - data of the last decade from Heidelberg University Hospital. [PDF]

Front Oncol
Bauer L, Paul A, Regnery S, Deng MY, Ellerbrock M, Mielke T, Harrabi SB, Seidensaal K, Held T, Herfarth K, Debus J, Hassel JC, Uzun-Lang K.   +12 more
europepmc   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

BMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang, Xueyin Hu, Wei Cheng, Lumeng Zhang, Yuanfang Chen, Qinrui Fu, Luntao Liu, Saijun Fan   +7 more
wiley   +1 more source

Prognostic implications of HIF-1α expression in anal squamous cell carcinoma treated with intensity-modulated radiotherapy (IMRT). [PDF]

Clin Transl Radiat Oncol
Mohamed AA, Eble MJ, Dahl E, Jonigk D, Warkentin S.   +4 more
europepmc   +1 more source

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

Cancer Communications, EarlyView.
Abstract Background Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)+ TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying ...
Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu   +11 more
wiley   +1 more source

Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation

Cancer Communications, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is a deadly malignancy known for its ability to evade immune surveillance. NOP2/Sun RNA methyltransferase family member 2 (NSUN2), an RNA methyltransferase involved in carcinogenesis, has been associated with immune evasion and energy metabolism reprogramming.
Jinhua Jiang, Feng Liu, Dan Cui, Caixia Xu, Jiachang Chi, Tinghua Yan, Fang Guo   +6 more
wiley   +1 more source

A dosimetric evaluation of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer in Ghana. [PDF]

Ecancermedicalscience
Kyei KA, Daniels J, Adom AK, Odonkor P, Nyantakyi AY, Adjabu DE.   +5 more
europepmc   +1 more source

Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway

Cancer Communications, EarlyView.
Abstract Background Radiotherapy (RT) is a key treatment modality in cancer therapy, utilizing high‐energy radiation to directly kill tumor cells. Recent research has increasingly highlighted RT's potential to indirectly enhance antitumor immunity. However, this immune activation alone often fails to generate sustained systemic antitumor responses.
Xuejiao Han, Yuan Cheng, Dandan Wan, Aqu Alu, Ziqi Zhang, Zhenfei Bi, Manni Wang, Yan Tang, Weiqi Hong, Siyuan Chen, Li Chen, Yuquan Wei   +11 more
wiley   +1 more source

Planning and Dosimetry Study of Dynamic Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Therapy for Carcinomas of the Pharynx Using 6MV Flattening Filter and Flattening Filter-free Beams. [PDF]

J Med Phys
Rajadurai E, Saravana Kumar A, Govindarajan KN, Pandu B, Jacob S.   +4 more
europepmc   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source